Hot Topic

AxoGen, Inc. Reports Financial Results for Third Quarter 2016

Written By: AxoGen Inc.

ALACHUA, Fla., Nov. 02, 2016 (GLOBE NEWSWIRE) — AxoGen, Inc., a global leader in innovative surgical solutions for peripheral nerve injuries, today announced financial results for the third quarter ended September 30, 2016 and provided a business update.

Third Quarter 2016 Financial and Recent Business Highlights

  • Third quarter revenue of $11.2 million up 37% compared to 2015 revenue of $8.2 million
  • Year-to-date revenue of $29.7 million up 52% compared to 2015 of $19.5 million
  • Gross margin of 84.9% compared to 2015 gross margin of 82.7%
  • Improved EBITDA loss of $1.1 million compared to 2015 EBITDA loss of $1.8 million
  • Increasing awareness of nerve injury and repair seen in multiple conference presentations at the Annual American Society for Surgery of the Hand Meeting and American Association of Oral and Maxillofacial Surgeons
  • Appointed former Covidien executive Amy Wendell to the Board of Directors
  • Raised $18.6 million in net proceeds through a public offering of common stock on October 13th
  • Refinanced $25.0 million debt facility on October 25th which will reduce annual interest costs by at least $1.5 million

“We are pleased with another successful quarter including record revenues of $11.2 million, continued growth in active and new accounts, and a significantly improved balance sheet” commented Karen Zaderej, President and Chief Executive Officer. “With a large presence at two recent medical meetings, it’s particularly pleasing to see surgeons becoming more familiar with the role of our portfolio of products for peripheral nerve repair.  Our recent equity raise and the refinancing of our debt provide us with a solid capital structure as we continue to drive awareness and growth in this emerging nerve repair market.”

Additional Operational and Financial Highlights

  • Increased active accounts in the third quarter to 414 up 40% from 296 a year ago
  • Ended the quarter with 45 direct sales representatives as compared to 38 a year ago; 23 independent agencies, consistent with prior year
  • Conducted 11 national education courses year to date and will complete two more for a total of 13 courses by the end of this calendar year
  • Ended the quarter with $16.0 million in cash and $25.0 million in debt
  • Use of cash in the quarter was $2.3 million
  • Seven peer reviewed publications year to date on the AxoGen nerve repair portfolio
  • After giving effect for the recent equity raise and debt refinancing as of September 30, 2016, pro forma cash was approximately $31.7 million and pro forma bank debt was approximately $25.0 million

2016 Financial Guidance 
Management maintains its full year 2016 revenue guidance of over $40 million and full year 2016 gross margin guidance to exceed 80%.

Introducing 2017 Financial Guidance
Management expects 2017 annual revenue will grow at least 40% over 2016 revenue and gross margins will remain above 80%.

Upcoming Events
The Company will be conducting its first Analyst and Investor Event on Monday, November 21st in New York City.  This event will include a review of clinical data and best practices in the repair of peripheral nerves from surgeons that use the AxoGen portfolio of products and a business review from Company management. Those interested in attending this event can register by sending an email to [email protected].

Conference Call
The Company will host a conference call and webcast for the investment community today at 4:30 PM ET. Investors interested in participating by phone are invited to call toll free at 1.877.407.0993 or use the direct dial-in number 1.201.689.8795. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the company’s website at and clicking on the webcast link on the Investors home page.

Following the conference call, a replay will be available on the Company’s website at www.AxoGenInc.comunder ‘Investors.’

About AxoGen
AxoGen (AXGN) is a global leader in innovative surgical solutions for peripheral nerve injuries. AxoGen’s portfolio of products includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard®Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Along with these core surgical products, AxoGen also offers AxoTouch™ Two-Point Discriminator and AcroVal™ Neurosensory & Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation, assessing return of sensory, grip and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom and several European and international countries.

Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “continue”, “may”, “should”, “will” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our 2016 guidance, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

About Non-GAAP Financial Measures
To supplement our consolidated financial statements, we use the non-GAAP financial measure of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization.

We use this non-GAAP financial measure for financial and operational decision-making and as a means to evaluate period-to-period comparisons.  We believe that this non-GAAP financial measure provides meaningful supplemental information regarding our performance and liquidity and that both management and investors benefit from referring this non-GAAP financial measure in assessing our performance and when planning, forecasting, and analyzing future periods.  We believe this non-GAAP financial measure is useful to investors because (1) it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) it is used by our institutional investors and the analyst community to help them analyze the performance of our business.

September 30, December 31,
2016 2015
Current assets:
Cash and cash equivalents $ 16,003,245 $ 25,909,500
Accounts receivable 7,004,756 4,782,989
Inventory 4,970,819 3,933,960
Prepaid expenses and other 685,711 424,925
Total current assets 28,664,531 35,051,374
Property and equipment, net 1,320,711 970,870
Intangible assets 787,523 678,082
$ 30,772,765 $ 36,700,326
Liabilities and Shareholders’ Equity (Deficit)
Current liabilities:
Accounts payable and accrued expenses $ 4,559,394 $ 3,695,127
Current deferred revenue 36,032 14,118
Total current liabilities 4,595,426 3,709,245
Note Payable – Revenue Interest Purchase Agreement 24,996,070 24,701,693
Long Term Deferred Revenue 77,610 93,797
Total liabilities 29,669,106 28,504,735
Shareholders’ equity: 302,090 299,846
Common stock, $.01 par value; 50,000,000 shares authorized;  30,209,036 and 29,984,591 shares issued and outstanding
Additional paid-in capital 113,058,408 111,368,424
Accumulated deficit (112,256,839) (103,472,679)
Total shareholders’ equity 1,103,659 8,195,591
$ 30,772,765 $ 36,700,326
Three and Nine Months ended September 30, 2016 and 2015
Three Months Ended Nine Months Ended
September 30, September 30, September 30,
2016 2015 2016 2015
Revenues $ 11,205,224 $ 8,153,675 $ 29,698,866 $ 19,522,244
Cost of goods sold 1,697,443 1,410,416 4,637,446 3,433,138
Gross profit 9,507,781 6,743,259 25,061,420 16,089,106
Costs and expenses:
Sales and marketing 7,090,059 5,512,613 20,076,297 14,257,397
Research and development 1,118,358 936,015 3,033,521 2,343,450
General and administrative 2,481,051 2,212,457 7,362,063 6,103,058
Total costs and expenses 10,689,468 8,661,085 30,471,881 22,703,905
Loss from operations (1,181,687) (1,917,826) (5,410,461) (6,614,799)
Other income (expense):
Interest expense (1,089,134) (1,042,258) (3,255,574) (3,060,779
Interest expense—deferred financing costs (31,748 ) (31,419 ) (95,254 ) (96,375)
Other income (expense) (2,804 ) 12,645 (22,871 ) 27,021
Total other income (expense) (1,123,686 ) (1,061,032 ) (3,373,699 ) (3,130,133)
Net loss $ (2,305,373 ) $ (2,978,858 ) $ (8,784,160 ) $ (9,744,932)
Weighted Average Common Shares outstanding – basic and diluted 30,152,279 26,841,060 30,075,715 24,778,123
Loss Per Common share – basic and diluted $ (0.08 ) $ (0.11 ) $ (0.29 ) $ (0.39)
Three and Nine Months ended September 30, 2016 and 2015
Three Months Ended Nine Months Ended
September 30, September 30, September 30,
2016 2015 2016 2015
Net loss $ (2,305,373 ) $ (2,978,858 ) $ (8,784,160 ) $ (9,744,932)
Depreciation and amortization expense 95,543 54,428 263,133 142,038
Amortization expense of intangible assets 16,017 11,299 48,050 34,009
Interest expense 1,089,134 1,042,258 3,255,574 3,060,779
Interest expense – deferred financing costs 31,748 31,419 95,254 96,375
EBITDA – non GAAP $ (1,072,931 ) $ (1,839,454 ) $ (5,122,149 ) $ (6,411,731)
Nine Months ended September 30, 2016 and 2015
2016 2015
Cash flows from operating activities:
Net loss  $ (8,784,160 ) $ (9,744,932)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation 263,133 142,038
Amortization of intangible assets 48,050 34,009
Amortization of deferred financing costs 95,253 96,375
Provision for bad debts 80,934
Stock-based compensation 1,046,364 1,031,218
Interest added to note 199,124 451,590
Change in assets and liabilities:
Accounts receivable (2,302,701 ) (1,770,494)
Inventory (1,036,859 ) (488,135)
Prepaid expenses and other (260,786 ) (180,862)
Accounts payable and accrued expenses 864,267 1,655,114
Deferred Revenue 5,727 (16,187)
Net cash used for operating activities (9,781,654 ) (8,790,266 )
Cash flows from investing activities:
Purchase of property and equipment (612,974 ) (353,093 )
Acquisition of intangible assets (157,491 ) (92,184 )
Net cash used for investing activities (770,465 ) (445,277 )
Cash flows from financing activities:
Proceeds from issuance of common stock 30,970,735
Debt issuance costs (180,142 )
Proceeds from exercise of stock options 645,864 164,626
Net cash provided by financing activities 645,864 30,955,219
Net increase / (decrease) in cash and cash equivalents (9,906,255 ) 21,719,676
Cash and cash equivalents, beginning of year 25,909,500 8,215,791
Cash and cash equivalents, end of period $ 16,003,245 $ 29,935,467
Supplemental disclosures of cash flow activity:
Cash paid for interest $ 3,031,528 $ 1,949,381

Leave a Comment